Polivy adcom: no overall survival, no problem
A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.
The next big tests for Argenx and its followers
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
The world needs Garp, according to Abbvie
After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression
39% of the patients assessed carried this biomarker, the conference presentation reveals.
